Finally, we explore future perspectives regarding the administration of GLP-1 analogues, GIP agonists, and probiotics/prebiotics as a means to prevent and combat NAFLD. The gene discussed is GIP; the disease is metabolic dysfunction-associated steatotic liver disease.